MX9505192A - Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico. - Google Patents

Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico.

Info

Publication number
MX9505192A
MX9505192A MX9505192A MX9505192A MX9505192A MX 9505192 A MX9505192 A MX 9505192A MX 9505192 A MX9505192 A MX 9505192A MX 9505192 A MX9505192 A MX 9505192A MX 9505192 A MX9505192 A MX 9505192A
Authority
MX
Mexico
Prior art keywords
reddening
utilization
treatment
pharmaceutical compositions
preparing pharmaceutical
Prior art date
Application number
MX9505192A
Other languages
English (en)
Inventor
Olivier De Lacharriere
Lionel Breton
Original Assignee
Oreal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9469930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9505192(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oreal filed Critical Oreal
Publication of MX9505192A publication Critical patent/MX9505192A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/046Tachykinins, e.g. eledoisins, substance P; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63Steroids; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67Vitamins
    • A61K8/671Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere al uso de un antagonista de la substancia P para la preparacion de una composicion farmacéutica, especialmente para aplicacion topica, para el tratamiento del enrojecimiento de la piel de origen neurogénico, y especialmente de la rosácea y del eritema pudendal. El antagonista de la substancia P puede ser un compuesto de péptido o un compuesto que contiene nitrogeno o un compuesto heterocíclico que contiene nitrogeno, que contiene azufre o que contiene oxígeno.
MX9505192A 1994-12-19 1995-12-11 Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico. MX9505192A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9415252A FR2728165A1 (fr) 1994-12-19 1994-12-19 Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene

Publications (1)

Publication Number Publication Date
MX9505192A true MX9505192A (es) 1997-04-30

Family

ID=9469930

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9505192A MX9505192A (es) 1994-12-19 1995-12-11 Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico.

Country Status (15)

Country Link
US (1) US5744156A (es)
EP (1) EP0722722B2 (es)
JP (1) JPH08208508A (es)
AR (1) AR000357A1 (es)
AT (1) ATE171372T1 (es)
BR (1) BR9505381A (es)
CA (1) CA2165518C (es)
DE (1) DE69504949T3 (es)
DK (1) DK0722722T4 (es)
ES (1) ES2124983T5 (es)
FR (1) FR2728165A1 (es)
HU (1) HU218944B (es)
MX (1) MX9505192A (es)
PL (1) PL311917A1 (es)
RU (1) RU2140263C1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732221B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2738742B1 (fr) * 1995-09-19 1997-11-14 Oreal Utilisation d'au moins une eau thermale de vichy en tant qu'antagoniste de substance p
EP0996461B1 (en) * 1997-10-31 2005-01-12 Walter Reed Army Institute of Research Use of a complement activation inhibitor in the manufacture of a medicament for inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
US6958148B1 (en) * 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
FR2774285B1 (fr) 1998-02-03 2001-06-15 Roche Posay Lab Pharma Utilisation d'une composition cosmetique pour le traitement et la prevention de la rosacee
US5972993A (en) * 1998-03-20 1999-10-26 Avon Products, Inc. Composition and method for treating rosacea and sensitive skin with free radical scavengers
AR018376A1 (es) * 1998-05-26 2001-11-14 Novartis Ag Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
DE10025553A1 (de) * 2000-05-24 2001-11-29 Merck Patent Gmbh Zusammensetzung, enthaltend mindestens ein Aryloxim und mindestens einen Wirkstoff zur Behandlung von Akne und ihre Verwendung
WO2003037334A1 (en) * 2001-10-31 2003-05-08 Merck & Co., Inc. Method for treating or preventing symptoms of hormonal variation including hot flashes
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
EP1600158A1 (en) * 2004-05-26 2005-11-30 Galderma Research & Development, S.N.C. Use of ondansetron for the treatment of inflammation, and pharmaceutical compositions thereof
FR2866566A1 (fr) * 2004-02-20 2005-08-26 Galderma Res & Dev Utilisation d'un inhibiteur de la secretion d'il-5,il-6 et/ou il-10 pour le traitement de la rosacee
US20070154448A1 (en) * 2005-11-22 2007-07-05 Ted Reid Methods and compositions using Substance P to promote wound healing
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
EP2075252B1 (en) 2006-10-16 2015-07-29 Lion Corporation Nk1 receptor antagonist composition

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5921656A (ja) 1982-07-28 1984-02-03 Takeda Chem Ind Ltd ポリペプチド誘導体
US4472305A (en) 1983-05-17 1984-09-18 Sterling Drug Inc. Hexapeptide amides
US4839465A (en) 1987-01-20 1989-06-13 Sterling Drug Inc. Di-(D-tryptophyl and/or tetrahydropyridoindolylcarbonyl)-containing peptide amides and process for preparation thereof
GB8807921D0 (en) 1988-04-05 1988-05-05 Fujisawa Pharmaceutical Co Ws-9326 & its derivatives
US5187156A (en) 1988-03-16 1993-02-16 Fujisawa Pharmaceutical Co., Ltd. Peptide compounds, processes for preparation thereof and pharmaceutical composition comprising the same
GB8807246D0 (en) 1988-03-25 1988-04-27 Merck Sharp & Dohme Therapeutic agents
EP0360390A1 (en) 1988-07-25 1990-03-28 Glaxo Group Limited Spirolactam derivatives
WO1990005525A1 (en) 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5164372A (en) 1989-04-28 1992-11-17 Fujisawa Pharmaceutical Company, Ltd. Peptide compounds having substance p antagonism, processes for preparation thereof and pharmaceutical composition comprising the same
FR2654725B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2654726B1 (fr) 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
GB8929070D0 (en) 1989-12-22 1990-02-28 Fujisawa Pharmaceutical Co Peptide compounds,processes for preparation thereof and pharmaceutical composition comprising the same
UA41251C2 (uk) 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
US5232929A (en) 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
WO1991012266A1 (en) 1990-02-15 1991-08-22 Fujisawa Pharmaceutical Co., Ltd. Peptide compound
KR0160142B1 (ko) 1990-05-31 1998-12-01 알렌 제이. 스피겔 치환된 피페리딘의 제조방법
HUT62891A (en) 1990-06-01 1993-06-28 Pfizer Process for producing 3-amino-2-arylquinuclidine compounds and pharmaceuticql composition comprising such compounds
DK0498069T3 (da) 1990-12-21 1995-12-04 Fujisawa Pharmaceutical Co Ny anvendelse af peptidderivat
AU652407B2 (en) 1991-01-10 1994-08-25 Pfizer Inc. N-alkyl quinuclidinium salts as substance P antagonists
ATE154354T1 (de) 1991-02-11 1997-06-15 Merck Sharp & Dohme Azabicyclische verbindungen, diese enthaltende pharmazeutische zubereitungen und ihre therapeutische verwendung
DE69200921T2 (de) 1991-03-01 1995-05-04 Pfizer 1-azabicyclo[3.2.2]nonan-3-aminderivate.
BR9205807A (pt) 1991-03-26 1994-06-28 Pfizer Preparação estéreo-seletiva de piperidinas substituidas
FR2677361A1 (fr) 1991-06-04 1992-12-11 Adir Nouveaux peptides et pseudopeptides, derives de tachykinines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2676442B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveau derives de perhydroisoindole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676446B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole, leur preparation et les compositions pharmaceutiques qui les contiennent.
FR2676447B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives du thiopyranopyrrole et leur preparation.
FR2676443B1 (fr) 1991-05-17 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux derives de perhydroisoindole et leur preparation.
DE69232334T2 (de) 1991-05-22 2002-11-14 Pfizer Inc., New York Substituierte 3-aminochinuclidine
GB9113219D0 (en) 1991-06-19 1991-08-07 Fujisawa Pharmaceutical Co Peptide compound,processes for preparation thereof and pharmaceutical composition comprising the same
UA39168C2 (uk) 1991-06-20 2001-06-15 Пфайзер, Інк. Фторалкоксифенільні похідні піперидину або хінуклідину, що є антагоністами речовини p і фармацевтична композиція на їх основі
TW202432B (es) 1991-06-21 1993-03-21 Pfizer
US5288730A (en) 1991-06-24 1994-02-22 Merck Sharp & Dohme Limited Azabicyclic compounds, pharmaceutical compositions containing them and their use in therapy
US5472978A (en) 1991-07-05 1995-12-05 Merck Sharp & Dohme Ltd. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
DE69208088T2 (de) 1991-07-05 1996-11-14 Merck Sharp & Dohme Aromatische verbindungen, diese enthaltende pharmazeutische zusammensetzungen und ihre therapeutische anwendung
US5495047A (en) 1991-07-10 1996-02-27 Merck, Sharp & Dohme (Ltd.) Fused tricyclic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
US5459270A (en) 1991-08-20 1995-10-17 Merck Sharp & Dohme Limited Azacyclic compounds, processes for their preparation and pharmaceutical compositions containing them
IL99368A (en) * 1991-09-02 1996-01-19 Teva Pharma Preparations for the treatment of psoriasis and atopic dermatitis, which contain the result of xanthine
BR9206500A (pt) 1991-09-26 1995-10-03 Pfizer Heterociclos contendo, nitrogênio tricíclico condensado como antagonistas de substancia receptora P
WO1993009116A1 (en) 1991-11-07 1993-05-13 Yoshitomi Pharmaceutical Industries, Ltd. Quinuclidine compound and medicinal use thereof
CA2083891A1 (en) 1991-12-03 1993-06-04 Angus Murray Macleod Heterocyclic compounds, compositions containing them and their use in therapy
GB9201179D0 (en) 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
JPH05339240A (ja) * 1992-06-04 1993-12-21 Yamanouchi Pharmaceut Co Ltd テトラヒドロイソキノリンアミド誘導体
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
GB9222486D0 (en) 1992-10-26 1992-12-09 Merck Sharp & Dohme Therapeutic agents
FR2719474B1 (fr) 1994-05-05 1996-05-31 Oreal Utilisation d'un antagoniste de substance P dans une composition cosmétique et composition obtenue.

Also Published As

Publication number Publication date
HUT74948A (en) 1997-03-28
ES2124983T3 (es) 1999-02-16
DK0722722T3 (da) 1999-06-14
JPH08208508A (ja) 1996-08-13
EP0722722B2 (fr) 2003-03-05
ES2124983T5 (es) 2003-11-16
EP0722722B1 (fr) 1998-09-23
HU9503625D0 (en) 1996-02-28
ATE171372T1 (de) 1998-10-15
DE69504949T2 (de) 1999-02-18
PL311917A1 (en) 1996-06-24
CA2165518A1 (fr) 1996-06-20
CA2165518C (fr) 2002-07-16
AR000357A1 (es) 1997-06-18
DE69504949D1 (de) 1998-10-29
DE69504949T3 (de) 2004-01-15
FR2728165B1 (es) 1997-02-07
EP0722722A1 (fr) 1996-07-24
HU218944B (hu) 2001-01-29
DK0722722T4 (da) 2003-07-07
RU2140263C1 (ru) 1999-10-27
US5744156A (en) 1998-04-28
BR9505381A (pt) 1997-11-18
FR2728165A1 (fr) 1996-06-21

Similar Documents

Publication Publication Date Title
MX9505182A (es) Composicion terapeutica para aplicacion topica, que contiene un antagonista de la substancia p.
MX9505192A (es) Utilizacion de un antagonista de la substancia p para la obtencion de composiciones farmaceuticas para el tratamiento del enrojecimiento cutaneo de origen neurogenico.
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
TR200103186T2 (tr) MEK enzimlerinin inhibitörleri olarak kinolin türevleri
MX9601150A (es) Uso de un antagonista del peptido derivado del gen de calcitonina para el tratamiento del erojecimiento cutaneo de origen neurogenico y composicion obtenida.
ZA975437B (en) New pyridyl alkene and pyridyl alkine acid amides.
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
EA199900532A1 (ru) Ингибиторы синтазы оксида азота
TR200103493T2 (tr) Metaloproteaz önleyicileri
MY133647A (en) Substituted quinoline-2-carboxamides, their preparation and their use as pharmaceuticals, and intermediates
BR0200782A (pt) Compostos para o tratamento da isquemia
TR199802136T2 (xx) �MPDH enzimi inhibit�rleri olarak �re t�revleri.
NO983189L (no) Nye substituerte imidazolforbindelser
ES2196396T3 (es) Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa.
BR0007589A (pt) Inibidores da proliferação de células
SE9802208D0 (sv) Novel compounds
YU13301A (sh) Muskarinski agonisti i antagonisti
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
SE9604348D0 (sv) Användning av hydroxyguanidiner
IL126110A0 (en) Use of aryl n-substituted carboxamides to kill tumors and novel compounds for such use
DE60101486D1 (de) Verwendung von Polyaminosäurederivate als Konservierungsmittel
FI970469A (fi) Bentsimidatsolijohdannaisia, joilla on dopaminerginen aktiivisuus
MD502G2 (ro) Derivaţi noi ai adenozinei, procedee de preparare a lor, compoziţii farmaceutice ce le conţin
ZA979647B (en) Heterocyclic compounds, compositions and uses.
DE59811656D1 (en) Kombinationspräparat aus 2-methylthiazolidin-2,4-dicarbonsäure und paracetamol